Distribution of the novel antifolate pemetrexed to the brain

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 1, 2005, Pages 222-229

  Dai, Haiqing ^a   Chen, Ying ^a   Elmquist, William F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID ANTAGONIST; INDOMETACIN; PEMETREXED; RALTITREXED;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTERIAL BLOOD; ARTICLE; BOLUS INJECTION; BRAIN PERFUSION; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INFUSION; DRUG TRANSPORT; FRONTAL CORTEX; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; STEADY STATE;

ANIMALS; AREA UNDER CURVE; BRAIN; CALIBRATION; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MICRODIALYSIS; RATS; RATS, WISTAR;

EID: 25644452036     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.090043     Document Type: Article

References (57)

1. Adjei AA (2000) Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 11:1335-1341.
2. Allen JC, Rosen G, Mehta BM, and Horten B (1980) Leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 64:1261-1273.
3. Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li WW, Fan J, Gorlick R, Goker E, and Bertino JR (1995) Molecular mechanisms of resistance to antifolates, a review. Acta Biochim Pol 42:457-464.
4. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, and de Vries EG (2000) The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 26:449-462.
5. Berger V, Gabriel AF, Sergent T, Trouet A, Larondelle Y, and Schneider YJ (2003) Interaction of ochratoxin A with human intestinal Caco-2 cells: possible implication of a multidrug resistance-associated protein (MRP2). Toxicol Lett 140-141:465-476.
6. Bertino JR (1993) Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 11:5-14.
7. Bleyer WA, Nelson JA, and Kamen BA (1997) Accumulation of methotrexate in systemic tissues after intrathecal administration. J Pediatr Hematol Oncol 19:530-532.
8. Bleyer WA, Pizzo PA, Spence AM, Platt WD, Benjamin DR, Kolins CJ, and Poplack DG (1978) The Ommaya reservoir: newly recognized complications and recommendations for insertion and use. Cancer 41:2431-2437.
9. Bouw MR, Xie R, Tunblad K, and Hammarlund-Udenaes M (2001) Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats-pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol 134:1796-1804.
10. Browne MJ, Dinndorf PA, Perek D, Commers J, Bleyer WA, Poplack DG, and Pizzo PA (1987) Infectious complications of intraventricular reservoirs in cancer patients. Pediatr Infect Dis J 6:182-189.
11. Chamberlain MC (1998) Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 37:271-284.
12. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, and Kruh GD (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62:3144-3150.
13. Chung C, Gottstein J, and Blei AT (2001) Indomethacin prevents the development of experimental ammonia-induced brain edema in rats after portacaval anastomosis. Hepatology 34:249-254.
14. Dai H and Elmquist WF (2003) Drug transport studies using quantitative microdialysis. Methods Mol Med 89:249-263.
15. Dakhil S, Ensminger W, Kindt G, Niederhuber J, Chandler W, Greenberg H, and Wheeler R (1981) Implanted system for intraventricular drug infusion in central nervous system tumors. Cancer Treat Rep 65:401-411.
16. DeAngelis LM (1999) Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. J Neurooncol 43:249-257.
17. Devineni D, Klein-Szanto A, and Gallo JM (1996) In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol 38:499-507.
18. Draper MP, Martell RL, and Levy SB (1997) Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer 75:810-815.
19. Dukic S, Heurtaux T, Kaltenbach ML, Hoizey G, Lallemand A, Gourdier B, and Vistelle R (1999) Pharmacokinetics of methotrexate in the extracellular fluid of brain C6-glioma after intravenous infusion in rats. Pharm Res 16:1219-1225.
20. Dukic SF, Heurtaux T, Kaltenbach ML, Hoizey G, Lallemand A, and Vistelle R (2000) Influence of schedule of administration on methotrexate penetration in brain tumours. Eur J Cancer 36:1578-1584.
21. Fox E, Bungay PM, Bacher J, McCully CL, Dedrick RL, and Balis FM (2002) Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. J Pharmacol Exp Ther 301:1003-1011.
22. Greenberg HS, Chandler WF, and Sandler HM (1999) Brain metastases, in Brain Tumors, pp 299-317, Oxford University Press, New York.
23. Hamilton KO, Topp E, Makagiansar I, Siahaan T, Yazdanian M, and Audus KL (2001) Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther 298:1199-1205.
24. Hasegawa H, Allen JC, Mehta BM, Shapiro WR, and Posner JB (1979) Enhancement of CNS penetration of methotrexate by hyperosmolar intracarotid mannitol or carcinomatous meningitis. Neurology 29:1280-1286.
25. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, and Jansen G (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532-2535.
26. Khamdang S, Takeda M, Noshiro R, Narikawa S, Enomoto A, Anzai N, Piyachaturawat P, and Endou H (2002) Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 303:534-539.
27. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, et al. (1999) MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96:6914-6919.
28. Lesniak MS, Langer R, and Brem H (2001) Drug delivery to tumors of the central nervous system. Curr Neurol Neurosci Rep 1:210-216.
29. Malhotra BK, Brundage RC, Lemaire M, and Sawchuk RJ (1997) Modeling the route of administration-based enhancement in the brain delivery of EAB 515, studied by microdialysis. J Drug Target 4:277-288.
30. Mason RW and McQueen EG (1974) Protein binding of indomethacin: binding of indomethacin to human plasma albumin and its displacement from binding by ibuprofen, phenylbutazone and salicylate, in vitro. Pharmacology 12:12-19.
31. Masuda S, Takeuchi A, Saito H, Hashimoto Y, and Inui K (1999) Functional analysis of rat renal organic anion transporter OAT-K1: bidirectional methotrexate transport in apical membrane. FEBS Lett 459:128-132.
32. Melera PW (1991) Acquired versus intrinsic resistance to methotrexate: diversity of the drug-resistant phenotype in mammalian cells. Semin Cancer Biol 2:245-255.
33. Morita N, Kusuhara H, Sekine T, Endou H, and Sugiyama Y (2001) Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther 298:1179-1184.
34. Mulato AS, Ho ES, and Cihlar T (2000) Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther 295:10-15.
35. O'Dwyer PJ, Nelson K, and Thornton DE (1999) Overview of phase II trials of MTA in solid tumors. Semin Oncol 26:99-104.
36. Ogiso T, Ito Y, Iwaki M, and Atago H (1989) A pharmacokinetic model for the percutaneous absorption of indomethacin and the prediction of drug disposition kinetics. J Pharm Sci 78:319-323.
37. Park DM and Abrey LE (2002) Pharmacotherapy of primary CNS lymphoma. Expert Opin Pharmacother 3:39-49.
38. Payen L, Courtois A, Campion JP, Guillouzo A, and Fardel O (2000) Characterization and inhibition by a wide range of xenobiotics of organic anion excretion by primary human hepatocytes. Biochem Pharmacol 60:1967-1975.
39. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, and Borst P (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 100:9244-9249.
40. Rosenberg GA (1990) Physiology of cerebrospinal and interstitial fluid, in Brain Fluids and Metabolism (Rosenberg GA ed) pp 36-57, Oxford University Press, New York.
41. Sawchuk RJ and Elmquist WF (2000) Microdialysis in the study of drug transporters in the CNS. Adv Drug Deliv Rev 45:295-307.
42. Sharp PE and La Regina MC (1998) Important biological features, in The Laboratory Rat (Suckow MA ed) p 12, CRC Press, Inc., Boca Raton, FL.
43. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, et al. (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123.
44. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, and Schultz RM (1998) Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 38:135-152.
45. Sosogi A, Gao F, Tomimatsu T, Hirata K, and Horie T (2003) Effects of non-steroidal anti-inflammatory drugs on the methotrexate transport in rat small intestine. Scand J Gastroenterol 38:43-49.
46. Stone JA, Castillo M, and Mukherji SK (1999) Leukoencephalopathy complicating an Ommaya reservoir and chemotherapy. Neuroradiology 41:134-136.
47. Sun H, Bungay PM, and Elmquist WF (2001a) Effect of capillary efflux transport inhibition on the determination of probe recovery during in vivo microdialysis in the brain. J Pharmacol Exp Ther 297:991-1000.
48. Sun H, Miller DW, and Elmquist WF (2001b) Effect of probenecid on fluorescein transport in the central nervous system using in vitro and in vivo models. Pharm Res 18:1542-1549.
49. Szentistvanyi I, Patlak CS, Ellis RA, and Cserr HF (1984) Drainage of interstitial fluid from different regions of rat brain. Am J Physiol 246:F835-F844.
50. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, and Endou H (2002) Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 302:666-671.
51. Volk EL, Farley KM, Wu Y, Li F, Robey RW, and Schneider E (2002) Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 62:5035-5040.
52. Volk EL and Schneider E (2003) Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538-5543.
53. Wang JJ, Freeman AI, and Sinks LF (1976) Treatment of acute lymphocytic leukemia by high-dose intravenous methotrexate. Cancer Res 36:1441-1444.
54. Wang Y and Sawchuk RJ (1995) Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J Pharm Sci 84:871-876.
55. Wang Y, Wong SL, and Sawchuk RJ (1993) Microdialysis calibration using retrodialysis and zero-net flux: application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus. Pharm Res 10:1411-1419.
56. Wilson CB and Norrell HA Jr (1969) Brain tumor chemotherapy with intrathecal methotrexate. Cancer 23:1038-1045.
57. Yang H, Wang Q, and Elmquist WF (1997) The design and validation of a novel intravenous microdialysis probe: application to fluconazole pharmacokinetics in the freely-moving rat model. Pharm Res 14:1455-1460.